Rare Histological Subtypes of Triple-Negative Breast Cancer: A Comprehensive Review Highlights Diagnostic and Therapeutic Implications
核心洞察
A new review examines rare histological subtypes of triple-negative breast cancer (搜索) (TNBC), which account for 10–15% of all TNBC cases and exhibit distinct biological behaviors and treatment responses.
The review emphasizes that standard TNBC treatment approaches may not be appropriate for all rare subtypes, with some requiring tailored therapeutic strategies based on unique molecular profiles.
Key rare subtypes discussed include metaplastic, adenoid cystic, medullary, and secretory carcinomas, each presenting unique diagnostic challenges and prognostic considerations.
Triple-negative breast cancer (搜索) (TNBC), defined by the absence of estrogen receptor, progesterone receptor, and HER2 expression, represents a heterogeneous disease entity that extends beyond the most common invasive ductal carcinoma of no special type. A comprehensive review published in npj Breast Cancer sheds light on the rare histological subtypes of TNBC, which collectively account for approximately 10–15% of all TNBC diagnoses, and underscores the critical importance of accurate pathological classification for guiding clinical management.
The review, authored by an international team of breast cancer researchers, provides a detailed examination of these uncommon variants, including metaplastic carcinoma, adenoid cystic carcinoma (搜索), medullary carcinoma (搜索), secretory carcinoma (搜索), and other rare entities. Each subtype presents distinct morphological features, molecular underpinnings, and clinical behaviors that diverge significantly from conventional TNBC.
Diagnostic Challenges and Molecular Characterization
Accurate diagnosis of rare TNBC subtypes remains a significant challenge in clinical practice. The review highlights that many of these entities can be misclassified as conventional TNBC without specialized pathological evaluation, potentially leading to suboptimal treatment decisions. Immunohistochemical profiling and, in select cases, molecular testing are essential tools for distinguishing these subtypes.
Metaplastic breast carcinoma (搜索), one of the more frequently encountered rare subtypes, is characterized by the differentiation of neoplastic epithelium into squamous cells or mesenchymal elements. This subtype typically demonstrates a more aggressive clinical course and relative resistance to conventional chemotherapy compared to other TNBC variants.
In contrast, adenoid cystic carcinoma (搜索) of the breast, which mirrors its salivary gland counterpart histologically, generally follows a more indolent clinical trajectory with a favorable prognosis. The review notes that this subtype harbors the characteristic MYB-NFIB (搜索) gene fusion, which can aid in diagnostic confirmation.
Therapeutic Implications
The review emphasizes that the standard-of-care chemotherapy regimens employed for conventional TNBC may not yield equivalent benefit across all rare histological subtypes. Certain variants, such as secretory carcinoma (搜索), which harbors the ETV6-NTRK3 (搜索) gene fusion, may be amenable to targeted therapy with TRK inhibitors, representing a paradigm shift from conventional cytotoxic approaches.
The authors stress that clinical trials specifically addressing rare TNBC subtypes are exceedingly limited, and most treatment recommendations are extrapolated from retrospective series and expert consensus. This evidence gap represents a significant unmet need in breast oncology.
Prognostic Considerations
Prognosis varies considerably across the rare TNBC subtypes. While adenoid cystic carcinoma (搜索) and secretory carcinoma (搜索) are generally associated with favorable long-term outcomes, metaplastic carcinoma and certain other variants carry a poorer prognosis. The review underscores that accurate subtyping has direct implications for risk stratification and follow-up intensity.
The authors call for increased multidisciplinary collaboration between pathologists, medical oncologists, and surgeons to ensure that patients with rare TNBC subtypes receive appropriately tailored care. Enhanced reporting standards and centralized pathology review in clinical trials are recommended to improve the evidence base for these uncommon malignancies.
Conflict of Interest Disclosures
Several authors disclosed relationships with pharmaceutical companies, including speaker fees, advisory roles, and institutional research funding from AstraZeneca, Daiichi Sankyo, Novartis, Roche, Pfizer, Gilead, and others, all reported as outside the submitted work.